SCHEMBL343739

SCHEMBL343739

CCC1=C2CC=CC=C2C(=O)c2ccccc2O1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.35
TSHR P16473 1/20 0.35
ACHE P22303 2/20 0.34
BCHE P06276 1/20 0.34
STK17B O94768 9/20 0.33
MIF P14174 2/20 0.33
HDAC3 O15379 2/20 0.32
HDAC4 P56524 2/20 0.32
HDAC1 Q13547 2/20 0.32
HDAC7 Q8WUI4 2/20 0.32
HDAC2 Q92769 2/20 0.32
HDAC10 Q969S8 2/20 0.32
HDAC11 Q96DB2 2/20 0.32
HDAC8 Q9BY41 2/20 0.32
HDAC6 Q9UBN7 2/20 0.32
HDAC9 Q9UKV0 2/20 0.32
HDAC5 Q9UQL6 2/20 0.32
MAOB P27338 3/20 0.32
ELANE P08246 2/20 0.32
MAOA P21397 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342143 0.69 PKM (0.39) PKMTSHRSTK17BMIFMAOB
Hydrochloric Acid SCHEMBL6411559 0.69 PKM (0.36) PKMTSHRACHESTK17BMIF
SCHEMBL12595955 0.65 KDM4E (0.44)
Acetic Acid SCHEMBL343376 0.64 PKM (0.34) PKMTSHRSTK17BMAOBMAOA
SCHEMBL29707476 0.60 PKM (0.54) PKMTSHRACHEBCHESTK17B
SCHEMBL290477 0.60 PKM (0.54) PKMTSHRACHEBCHESTK17B
SCHEMBL8780706 0.60 PKM (0.39) PKMTSHRACHEBCHESTK17B
SCHEMBL1950924 0.60 PKM (0.39) PKMTSHRACHEBCHESTK17B
SCHEMBL2406498 0.60 GSK3B (0.33)
SCHEMBL3707104 0.60 CDC25B (0.41) PKMACHEBCHEMAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2393797-B1 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZACH SYSTEM SPA (IT) 2016-04-20 EP disclosed
US-8835655-B2 Process for preparing olopatadine and/or a pharmaceutically acceptable salt thereof ZACH SYSTEM S.P.A (IT) 2014-09-16 US disclosed
US-20120016138-A1 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZACH SYSTEM S.P.A. (IT) 2012-01-19 US disclosed
EP-2393797-A2 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZaCh System S.p.A. (IT) 2011-12-14 EP disclosed
WO-2010089268-A2 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZACH SYSTEM S.P.A. (IT) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016138-A1 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF QDPR, OPRD1, O60361 PKM 3239/4885TSHR 3236/4885ACHE 545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.